对患有转移性瘤基因驱动的非小细胞肺癌患者的混合息和生存护理干预 (POISE):试点随机对照试验的研究协议
Heather A Richard1, Roshni Sarathy2, Dustin J Rabideau2
1College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
BMJ open
|August 14, 2025
概括
这项试点研究评估了针对晚期肺癌患者的以患者为中心,最佳整合生存和息护理 (POISE) 干预措施. POISE的目标是改善这些幸存者的生活质量,并应对这些幸存者的不确定性.
科学领域:
- 在瘤学瘤学.
- 抚慰性护理是一种缓解性护理.
- 临床试验 临床试验
背景情况:
- 精准医学的进步使得转移性癌基因驱动的非小细胞肺癌 (NSCLC) 患者的生命轨迹更长,更不确定.
- 这些患者面临着与生活不确定性相关的独特挑战,需要加强支持性护理.
- 针对具有特定驱动突变 (EGFR,ALK,ROS1,RET) 的NSCLC的向治疗需要量身定制的生存和息护理干预措施.
研究的目的:
- 为患有转移性瘤基因驱动NSCLC的患者开发和试验混合息和幸存者护理干预 (POISE).
- 评估POISE干预的可行性和可接受性.
- 探索POISE对情绪应对,自我效能,预后意识,生活质量和其他患者报告结果的影响.
主要方法:
- 一个单一的,非盲目的试点随机对照试验,将POISE干预与常规护理进行比较.
- 在马萨诸塞州总医院癌症中心招募60名转移性癌基因驱动NSCLC患者.
- POISE干预包括与息护理临床医生进行结构化访问,重点关注不确定性,预后意识和健康的生活方式;通常护理患者接受标准瘤护理.
主要成果:
- 通过招生率 (≥60%),干预会议完成率 (≥70%) 和调查完成率 (≥70%) 来评估可行性.
- 探索性结果包括可接受性,情绪应对,自我效能,预后意识,生活质量,焦虑,抑郁,不容忍不确定性以及对护理目标讨论的记录.
结论:
- POISE干预是一种新的方法,用于解决针对性治疗中高级NSCLC患者未得到满足的支持性护理需求.
- 试点数据将为这群人群整合息治疗和幸存者护理的可行性和潜在好处提供信息.
- 这项研究旨在改善瘤基因驱动肺癌幸存者的生活质量和应对机制.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.2K
07:44Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
10.2K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
